Introduction
When DNA in colon epithelium is damaged by genotoxins and not repaired, mutations may become formed and the multistage process of colon cancer initiated. If mutations occur at sites that regulate cell growth functions, cell division of affected cells could enhance the development of benign preneoplastic lesions (polyps). Furthermore, polyps carry a potential to transform into neoplastic lesions leading to colon cancer development (1) (2) (3) (4) (5) .
DNA lesions can be generated by reactive electrophilic metabolites that bind covalently to nucleophilic sites of DNA and thus form DNA adducts (6, 7) . DNA adducts are considered as biomarkers of cancer risk in exposed populations (8, 9) , being related to tumour formation in laboratory animals (10) and clinically observed cancer (11) . Furthermore, DNA adducts represent a very early, detectable and critical step in the process of chemical carcinogenesis (12) (13) (14) .
The 32 P-high-performance liquid chromatography (HPLC) method enables analysis of DNA adducts, with a high sensitivity and an efficient chromatographic separation, thus allowing single DNA adducts to be detected in complex mixtures (8, 10, 15) . The presence of aromatic DNA adducts in human colonic mucosa has been reported (16) and DNA adducts of the colonic mucosa can presumably be involved in the development of colon cancer (17) . In a study on colon cancer patients, the level of DNA adduct from colonic mucosa was examined (18) . Subjects without colon cancer (control colon and cured sigmoiditis controls) had a significantly lower level of DNA adducts than did the mucosa adjacent to tumours in the colon cancer patients.
Further, long-term animal studies have shown a carcinogenic effect of food-derived heterocyclic amines (19) , and DNA adduct formation of the heterocyclic amines in human tissues has been reported (20, 21) .
The aim of this study was to investigate whether there are differences in DNA adduct levels and patterns in normal mucosa from patients with colon cancer, polyps and non-cancerous controls analysed by the 32 P-HPLC method. Further, the aim was to investigate whether some DNA adducts could be markers for colon cancer development.
Material and methods

Patients and tissue specimens
The healthy controls (n 5 10) were recruited from patients undergoing colonoscopy without any endoscopic or clinical signs of colorectal polyps or of inflammatory bowel disease, thus displaying a normal macroscopic colonic mucosa. Biopsies were taken from the ascending, transverse and descending colon, fixed in 4% formaldehyde and evaluated histologically. These biopsies showed a normal colonic mucosa in all individuals included as controls. In addition, from each control, nine mucosal biopsies were taken from the ascending, transverse and descending colon (three biopsies from each location) for DNA adduct analysis. The biopsies were rinsed in 0.9% NaCl, air-dried, pooled and immediately frozen at À70°C for later DNA adduct determination and were labelled 'colon mucosa from control' (C). Since biopsies were taken at routine colonoscopy and there was a scarcity of tissue material for adduct analyses, samples from the different parts of colon were pooled.
Polyp patients (n 5 22) were included. These were patients in whom colonoscopy showed at least one colorectal polyp with a size . 1 cm. The polyps were removed by diathermic polypectomy, and the size of the fresh polyp was measured. Half of the distal tips of the polyp ($25% of the size of the polyp) were cut off, rinsed in 0.9% NaCl, air-dried and immediately frozen at À70°C for later DNA adduct determination. Specimens were labelled 'polyp tissue' (P). The remaining three-quarters of the polyps (including the whole base) were fixed in 4% formaldehyde for histological evaluation. At histology, polyps were classified as tubular, villous or tubulovillous adenomas. If dysplasia was present, it was ranked low or high grade. In addition, nine mucosal biopsies were taken from the ascending, transverse and descending colon, similarly as was done in the healthy controls. These biopsies were labelled 'mucosa adjacent to polyp' (NP). Cancer patients (n 5 32) with a diagnosed colorectal carcinoma were included. After colonic resection, a small part of the tumour was cut off at the central portion, rinsed in 0.9% NaCl, air-dried and immediately frozen at À70°C for later DNA adduct determination. These specimens were labelled 'tumour tissue' (T). Biopsies were also taken from the colonic mucosa adjacent to the tumour, at the distances 1 and 10 cm from the tumoural margin, for DNA adduct analysis. These biopsies were labelled 'nontumour tissue 1 and 10 cm' (NT 1 and NT 10 , respectively). The remainder of the colorectal specimens were evaluated histologically. Each patient was classified according to Duke's classification of colon cancer. Tumour size and differentiation grade of the tumours (high, intermediate or low) were determined.
Questionnaire and consent
All patients answered a questionnaire regarding age, sex, residence (city or rural area), alcohol consumption, cigarette smoking and exposure to chemical solvents. Informed consent was given by all patients and controls. The study was approved by the Ethical Committee at the Karolinska Institute, Huddinge University Hospital, Huddinge, Sweden.
Standards
The heterocyclic amines 2-amino-9H-pyrido [2,3- 
DNA preparations
Tissues were homogenised in 10 ml/g tissue of sodium dodecyl sulphateethylenediaminetetraacetic acid buffer (1% sodium dodecyl sulphate, 1 mM ethylenediaminetetraacetic acid disodium salt) and 240 ll/g tissue of Tris[hydroxymethyl]aminoethane (Tris)-HCl buffer (1 M Tris-HCl, sodium hydroxide to pH 7.4) at 0°C. The DNA was isolated by digestion with 240 ll (120 U)/g tissue of ribonuclease (RNase) A (10 mg/ml RNase from bovine pancreas, heat-inactivated by a 3 min incubation at 100°C in 50 mM Tris-HCl buffer, pH 7.4) (Boehringer Mannheim GmbH, Mannheim, Germany) and 80 ll/ g tissue of RNase T1 (5 U/ll RNase T1 from Aspergillus oryzae in 50 mM TrisHCl buffer, pH 7.4) (Sigma Chemical, Cleveland, OH, USA) for 2 h at 37°C. Thereafter, 600 ll/g tissue of protease (10 mg/ml protease from Streptomyces griseus, heat inactivated by a 2 h incubation at 37°C, in 50 mM Tris-HCl buffer, pH 7.4) was added, and the mixture was incubated for 30 min at 37°C. The mixture was then extracted with 10 ml/g tissue of phenol (saturated with 50 mM Tris-HCl buffer pH 7.4) and centrifuged at 4000 Â g for 10 min. Thereafter, the aqueous phase was extracted with 10 ml/g tissue of phenol-sevag (50% phenol, 48% chloroform and 2% isoamyl alcohol) and centrifuged at 4000 Â g for 10 min. Following this, the aqueous phase was extracted with 10 ml/g tissue of sevag (96% chloroform and 4% isoamyl alcohol) and centrifuged at 4000 Â g for 10 min. The DNA was precipitated with 0.1 volume 5 M NaCl and 1 volume 95% ethanol. After centrifugation and a wash with 70% ethanol, the DNA was re-dissolved in water (1 ml/g tissue). Finally, the DNA concentration and purity were measured by ultraviolet spectrometry. The DNA was dried through evaporation in a Speedvac (VLP120, Savant Instruments, Holbrook, NY, USA) and stored in a non-hydrolysed form at À70°C until analysis.
32
P-postlabelling Aliquots of 10 lg DNA dissolved (to 0.5 lg/ll) in water were hydrolysed by the addition of 80 mU/lg DNA micrococcal nuclease (0.2 U/ll from Staphylococcus aureus Foggis strain; Sigma Chemical), 5 ll of 3 mM bicine (pH 9.0) and 5 ll of 0.5 mM CaCl 2 and incubated at 37°C for 2 h. Thereafter, 1.6 mU/lg DNA of spleen phosphodiesterase (1 mU/ll dialysed phosphodiesterase from calf spleen in 10 mM ammonium acetate, pH 5.0) (Boehringer Mannheim GmbH) was added, and the mixture was incubated for 2 h at 37°C. The DNA and nucleotide samples were adduct-enriched by butanol extraction and then enzymatically P-HPLC method with gradient modifications was performed according to Zeisig and Möller (25) .
Statistical analysis DNA adducts levels between different tissues were compared by analysis of variance (Fisher's PLSD). A P-value ,0.05 was considered statistically significant.
Results
Comparison of the total aromatic DNA adduct level using the 32 P-HPLC method revealed no significant differences between colon tissue specimens from controls, polyp patients and colon cancer patients (Figure 1) . Levels of individual DNA adducts are shown in Tables I and II . Levels of DNA adducts E, G and L were significantly lower in tumour tissue and colon mucosa adjacent to colorectal carcinomas compared to tissue from controls. For two single DNA adducts (G and L), a trend was seen in the average single DNA adduct levels, indicating lower adduct levels in mucosa adjacent to colon cancer tissue, as compared with non-polyp mucosa from polyp patients or colon mucosa from controls. One of the DNA adducts (M) was only found in some of the tumour (T, NT 1 and NT 10 ) tissues, and neither in controls nor in polyp patients (Table III and Figure 2) .
In controls, polyp and cancer patients, no correlations were found between total DNA adduct levels and age, sex, smoking and drinking habits or exposure to urban traffic and chemicals. Polyp and tumour size did not correlate with total DNA adduct levels and nor did differentiation grade of tumours in the cancer patients.
Retention times of DNA adducts from benzo[a]pyrene and heterocyclic amines (4,8-diMeIQx, AaC and PhIP) were analysed and compared with those of the DNA adducts in the colon tissues. A minor PhIP-DNA adduct standard had a retention time in 32 P-HPLC identical to that of the human DNA adduct H. The result from co-chromatography also showed identical retention time, which suggests that the DNA adduct H was related to PhIP (Figure 3 ). This was also confirmed by using a gradient-modified 32 P-HPLC method, permitting higher resolution at the retention times around the peak of interest. The PhIP-related DNA adduct was found in 106 of 150 tissues from control (70%), polyp (77%) and cancer (NT 10 75%, NT 1 56% and T 63%) subjects. The tumour tissue (T) and mucosa 1 cm from the tumours (NT 1 ) had significantly lower levels of the PhIP-related DNA adduct H compared to the non-polypous mucosa from polyp patients (NP), whereas there were no statistically significant differences compared with the other groups (Table IV) .
Discussion
Previous studies of aromatic DNA adducts in human colon tissues (Table V) have shown the presence of DNA adducts in colonic mucosa (16) , and it was concluded that DNA adducts in the colon mucosa could be responsible for the development of colon cancer (17) . In one study on colon cancer patients (18), the total number of DNA adducts from colon mucosa was investigated. Mucosa adjacent to the tumours in colon cancer patients had a significantly higher number of DNA adducts than did mucosa from the controls (i.e. non-cancer patients). The present study could not confirm these findings. No statistically significant differences in total DNA adduct levels were found between control, polyp or colorectal mucosa when totally 150 biopsies were analysed (Figure 1 ). Regarding specific DNA adducts, we found lower levels of the DNA adducts E, G and L in tissue from tumour patients than in tissue from controls or polyp patients. As seen in Figure 2 , colon tissue from tumour patients had significantly lower levels of the DNA adducts G and L compared to the other groups. This unexpected finding became contrasts to the average level of the remaining DNA adducts, which were present at the same level in all tissues. A possible explanation to the finding is that tissues may develop a drug resistance during the process of carcinogenesis (26) , which affects the metabolism of mutagens, leading to resistance to chemical agents forming DNA adducts.
In contrast to the DNA adducts G and L, the adduct M was only present in tissues of colon cancer patients (T, NT 1 and NT 10 ), and neither detected in any colonic tissue from polyp patients (NP and P) nor controls (C). However, the DNA adduct M was only found in 25% of colon cancer patients, indicating a possible subgroup of colon cancer patients with a specific lack of DNA repair. Therefore, the adduct M could not by itself serve as a biomarker for colon cancer or a marker for increased cancer risk. Whether or not it could be used as a risk marker for colorectal carcinoma in conjunction with the DNA adducts G and L, which show decreased levels in colonic Fig. 1 . Total DNA adduct levels in human colon samples seen in 32 P-HPLC analysis. Levels shown are mean AE standard deviation and are expressed as DNA adducts per 10 8 normal nucleotides (NN). Bar 1 corresponds to colon mucosa from control patients (C) (n 5 10); bar 2 corresponds to mucosa adjacent to the polyps (NP) (n 5 22); bar 3 represents mucosa from polyps (P) (n 5 22); bar 4 corresponds to mucosa adjacent to and distanced 10 cm from the tumours (NT 10 ) (n 5 32); bar 5 represents mucosa adjacent 1 cm from the tumours (NT 1 ) (n 5 32) and bar 6 corresponds to mucosa from the tumours of cancer patients (T) (n 5 32). No significant differences of total DNA adduct levels were observed. mucosa adjacent to tumour tissue ( Figure 2 ) needs to be further investigated.
The presence of food-derived DNA adducts has been observed in colorectal mucosa (27) . It is known that genotoxic substances are produced in cooked meat, which may contribute to the incidence of colon cancer. Heterocyclic amines represent the most important group of food mutagens and are considered significant because they are produced at temperatures used to grill, fry or broil red meats, poultry and fish (28) . The heterocyclic amines are also found in cigarette smoke (29) . They are mutagenic in bacterial assays (30) and in rodents (31) and some of them have been shown to induce hepatocellular carcinomas in non-human primates (32) . Furthermore, DNA adducts levels of heterocyclic amines correlate with exposure, but they are not highly correlated with tissue-specific tumour development (33) .
One example of heterocyclic amines present in cooked food is [2-14C] 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline (MeIQx). In one study, MeIQx was orally administered to colon cancer patients, where it was shown that MeIQx formed DNA adducts in the human colon. However, no difference in adduct levels was seen between cancer patients given the substance and patients not receiving it (34) . Another heterocyclic amine considered to be a colon cancer risk factor is PhIP (35) . It forms DNA adducts in rats, in which it enhances proliferation in colonic mucosa. This leads to aberrant crypt foci formation that are considered to be preneoplastic lesions (36) . PhIP has also been shown to leave characteristic mutational fingerprints in the Apc gene. Such mutations have been detected in rat colon tumours, but Apc gene mutations are also known to be involved in human colon cancer (37) . In orally administered colon cancer patients, it was shown that PhIP form DNA adducts. The presence of PhIP-DNA adducts in colonic mucosa of cancer patients administered PhIP was significantly higher than in mucosa from cancer patients not exposed to PhIP (35) . Another study showed that the urinary metabolite profile of PhIP was a good predictor of colon DNA adducts after a low-dose exposure of PhIP in humans (38) .
In the present study, by co-chromatography with both the normal 32 P-HPLC method and the gradient-modified 32 P-HPLC method (24), a minor PhIP-related DNA adduct was shown to have the same retention time as the DNA adduct H in the colonic tissues ( Figure 3 ). It therefore makes the DNA adduct H to be a candidate PhIP-related DNA adduct. To confirm that the DNA adduct H is PhIP-related, structural analysis are needed. One limitation though, is that the 32 P-HPLC method is such a sensitive method, that the need for larger amounts of DNA for structural analysis sets the limit (39) . The PhIP-related DNA adduct H was found in 106 of the 150 colon tissues studied, which comprised all the kinds of tissues (C, NP, P, NT 1 , NT 10 and T). There was no significant difference between the PhIP-related DNA adduct H levels between tissue from controls, polyp patients or mucosa 10 cm from the tumours. Interestingly, the lowest levels were found in tumour tissue. Neoplastic tissue possibly do not accumulate adducts to the same extent as nonneoplastic tissue do, due to its high cell proliferation resulting in shorter exposure time. Taken together, although PhIP is a wellknown carcinogen in experimental animal models, the presented data speaks against PhIP being a significant factor in human colon carcinogenesis in vivo.
In conclusion, we found no differences regarding the total level of DNA adducts in the different colonic tissues from controls, polyp or cancer patients, and no correlation between DNA adduct levels and smoking and drinking habits, urban or rural residence, histology or differentiation grade of tumours. One DNA adduct (M) was found only in the mucosa from the colon cancer patients, both in the tumours and in tissue adjacent to the neoplastic lesions, indicating a possible role during colon carcinogenesis. However, it was found in only 25% of the cancer patients, why it cannot be used as a general risk marker for development of colon cancer in a clinical setting. The DNA adducts G and L were significantly decreased in colonic mucosa adjacent to the tumours, making them interesting candidates for further evaluation, in conjunction with the elevated adduct M in the same mucosa, of their possible role as biomarkers in human carcinogenesis. The PhIP-related DNA adduct H was significantly decreased in the tumours, but without any significantly different levels in colon mucosa from controls, polyp patients or that taken 10 cm from tumours, indicating minor importance of this DNA adduct in human colon carcinogenesis. 
